WT1 protein expression in childhood acute leukemia
✍ Scribed by Gunter Kerst; Nina Bergold; Friederike Gieseke; Elaine Coustan-Smith; Peter Lang; Marketa Kalinova; Rupert Handgretinger; Jan Trka; Ingo Müller
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 230 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In patients with acute leukemia, Wilms' tumor gene 1 (WT1) has been used as a target for the detection of minimal residual disease (MRD) by PCR techniques. The expression of WT1 protein, however, has not been extensively studied. To determine the relation between expression of WT1 transcripts and of the encoded protein, we examined leukemic cell lines and primary childhood leukemia samples using both real‐time quantitative PCR (RQ‐PCR) and flow cytometry. WT1 protein was highly expressed in the leukemic cell lines K562, HL‐60, PLB 985, KG‐1a and CEM. By contrast, 40 primary samples of acute lymphoblastic leukemia (ALL; B‐ALL, n = 15 and T‐ALL, n = 10) and acute myeloid leukemia (n = 15) expressed low levels of WT1 protein. RQ‐PCR detected WT1 transcript levels in the same range as reported in earlier studies in childhood acute leukemia. The results of this study indicate the following: (i) there are considerable discrepancies between WT1 transcripts and protein expression; (ii) WT1 is not a suitable marker for flow cytometric MRD detection in childhood acute leukemia. Am. J. Hematol., 2008. © 2007 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Aberrant CD2 expression in childhood precursor-B ALL is rare and has recently been reported with an incidence of 3.6% in a study by Cantu-Rajnoldi et al. [Haematologica 77:384, 19921. There was no association of the CD2 co-expression with other known prognostic factors. Our study represents the seco
The WT1 gene encodes a transcriptional regulator which during embryogenesis is involved in growth control and differentiation of diverse tissues. It is also expressed in few human malignancies, including acute leukemia. We tested 3 different monoclonal antibodies (MAbs H2, H7, HC17) and the polyvale
## BACKGROUND. Although it is widely accepted that failure to achieve complete remission (CR) portends a poor prognosis in childhood acute lymphoblastic leukemia (ALL), there is variability in the precise definition of induction failure and, to the authors' knowledge, few published data exist regar